109 related articles for article (PubMed ID: 33200225)
21. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
Fan Q; Cai Q; Xu Y
Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
[TBL] [Abstract][Full Text] [Related]
22. Structure-based virtual screening towards the discovery of novel FOXM1 inhibitors.
Xie ZS; Zhou ZY; Sun LQ; Yi H; Xue ST; Li ZR
Future Med Chem; 2022 Feb; 14(4):207-219. PubMed ID: 34809496
[No Abstract] [Full Text] [Related]
23. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Srivastava RK; Shankar S
Cancer Lett; 2014 Oct; 353(1):32-40. PubMed ID: 25050737
[TBL] [Abstract][Full Text] [Related]
24. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
[TBL] [Abstract][Full Text] [Related]
25. Rottlerin, a natural polyphenol compound, inhibits upregulation of matrix metalloproteinase-9 and brain astrocytic migration by reducing PKC-δ-dependent ROS signal.
Lee TH; Chen JL; Liu PS; Tsai MM; Wang SJ; Hsieh HL
J Neuroinflammation; 2020 Jun; 17(1):177. PubMed ID: 32505192
[TBL] [Abstract][Full Text] [Related]
26. Rottlerin inhibits tonicity-dependent expression and action of TonEBP in a PKCdelta-independent fashion.
Zhao H; Tian W; Cohen DM
Am J Physiol Renal Physiol; 2002 Apr; 282(4):F710-7. PubMed ID: 11880333
[TBL] [Abstract][Full Text] [Related]
27. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
28. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.
Chen L; Cheng X; Tu W; Qi Z; Li H; Liu F; Yang Y; Zhang Z; Wang Z
Cell Oncol (Dordr); 2019 Oct; 42(5):679-690. PubMed ID: 31325096
[TBL] [Abstract][Full Text] [Related]
29. Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness.
Battistini C; Kenny HA; Zambuto M; Nieddu V; Melocchi V; Decio A; Lo Riso P; Villa CE; Gatto A; Ghioni M; Porta FM; Testa G; Giavazzi R; Colombo N; Bianchi F; Lengyel E; Cavallaro U
Cell Death Dis; 2024 May; 15(5):370. PubMed ID: 38806454
[TBL] [Abstract][Full Text] [Related]
30. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
31. FoxM1 promotes the migration of ovarian cancer cell through KRT5 and KRT7.
Zhang Z; Tu K; Liu F; Liang M; Yu K; Wang Y; Luo Y; Yang B; Qin Y; He D; Jiang G; Huang O; Zou Y
Gene; 2020 Oct; 757():144947. PubMed ID: 32659254
[TBL] [Abstract][Full Text] [Related]
32. Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy.
Gu L; Liu HM
World J Pediatr; 2020 Apr; 16(2):113-119. PubMed ID: 31190319
[TBL] [Abstract][Full Text] [Related]
33. MiR-216b inhibits osteosarcoma cell proliferation, migration, and invasion by targeting Forkhead Box M1.
Wang W; Guo Z; Yu H; Fan L
J Cell Biochem; 2019 Apr; 120(4):5435-5443. PubMed ID: 30302807
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1.
Liu X; Xie T; Mao X; Xue L; Chu X; Chen L
Cell Physiol Biochem; 2016; 39(2):617-29. PubMed ID: 27415661
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
[TBL] [Abstract][Full Text] [Related]
36. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
37. Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer.
Llauradó M; Majem B; Castellví J; Cabrera S; Gil-Moreno A; Reventós J; Ruiz A
Mol Cancer Res; 2012 Jul; 10(7):914-24. PubMed ID: 22589409
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of FoxM1 by MnSOD Overexpression Contributes to Cancer Stem-Like Cell Characteristics in the Lung Cancer H460 Cell Line.
Fu Z; Cao X; Yang Y; Song Z; Zhang J; Wang Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818789635. PubMed ID: 30111255
[TBL] [Abstract][Full Text] [Related]
39. Evidence that protein kinase Cdelta is not required for palmitate-induced cytotoxicity in BRIN-BD11 beta-cells.
Welters HJ; Smith SA; Tadayyon M; Scarpello JH; Morgan NG
J Mol Endocrinol; 2004 Feb; 32(1):227-35. PubMed ID: 14766004
[TBL] [Abstract][Full Text] [Related]
40. Rottlerin inhibits the nuclear factor kappaB/cyclin-D1 cascade in MCF-7 breast cancer cells.
Torricelli C; Fortino V; Capurro E; Valacchi G; Pacini A; Muscettola M; Soucek K; Maioli E
Life Sci; 2008 Mar; 82(11-12):638-43. PubMed ID: 18261747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
